Brief: Zealand Pharma Says Survodutide Achieves Up To 13.1% Weight Loss In Phase III Trial

Zealand Pharma A/S

01/10/2026 08:35

Oct 1 (Reuters) - Zealand Pharma A/S ZELA.CO:
REG-ZEALAND PHARMA ANNOUNCES BOEHRINGER INGELHEIM’S SURVODUTIDE ACHIEVES UP TO 13.1% WEIGHT LOSS IN NEW PHASE III TRIAL, ALONGSIDE SIGNIFICANT IMPROVEMENTS IN GLYCEMIC CONTROL IN PEOPLE WITH OBESITY AND TYPE 2 DIABETES
PARTICIPANTS EXPERIENCING A REDUCTION OF UP TO 1.21% IN HBA1C USING EFFICACY ESTIMAND
TRIAL ALSO MET ITS OTHER CO-PRIMARY ENDPOINT, WITH UP TO 79.3% OF ADULTS TREATED WITH SURVODUTIDE ACHIEVING BODY WEIGHT REDUCTION OF ≥5%
Source text: ID:nGNE2h3RVl
Further company coverage: ZELA.CO

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))